Impact of traits of metabolic syndrome on β-cell function and insulin resistance in normal fasting, normal glucose tolerant subjects

Metabolic Syndrome and Related Disorders

Volumn 10, Issue 5, 2012, Pages 344-350

  Cubeddu, Luigi X ^a,b   Hoffmann, Irene S ^b  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; ARTICLE; CONCENTRATION (PARAMETERS); DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SCREENING;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; FASTING; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEALTH STATUS INDICATORS; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS;

EID: 84872869796     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2012.0040     Document Type: Article

References (24)

1. Unwin N, Shaw J, Zimmer P, Alberti KGMM. Impaired glucose tolerance and impaired fasting glycemia: The current status on definition and intervention. Diabet Med 2002;19: 709-723.
2. The Expert Committee on the Diagnostic and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnostic and Classification of Diabetes Mellitus. Diabetes Care 2008;31:562-567.
3. Abdul-Ghani MA, Abdul-Ghani T, Ali N, Defronzo RA. One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care 2008;31:1650-1655.
4. Abdul-Ghani MA, Lyssenko V, Tuomi T, et al. Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: Results from the Botnia Study. Diabetes Care 2009;32:281-286.
5. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease and all causes in United States adults. Circulation 2004;110:1245-1250.
6. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as predictor of coronary heart disease and diabetes in the West Scotland Coronary Prevention Study. Circulation 2003;108:414-419.
7. Hunt KH, Resendez RG, Williams K, et al. National Cholesterol Education program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110:1251-1257.
8. Tennenbaum A, Fisman EZ. "The metabolic syndrome is dead": These reports are an exaggeration. Cardiovasc Diabetol 2011;10:11-14.
9. Lindstrom J, Tuomillehto J. The diabetes risk score: A practical tool to predict type 2 diabetes at risk. Diabetes Care 2003;6:725-731.
10. DeFronzo RA. Lilly lecture 1987: The triumvirate: Beta-cell, muscle liver: A collusion responsible for NIDDM. Diabetes 1988;37:667-687.
11. Hanson RL, Pratley RE, Bogardus C, et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 2000;151: 190-198.
12. Abdul-Ghani MA, Matsuda M, Jani R, et al. The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab 2008;295:401-406.
13. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 1999; 22:1462-1470.
14. Abdul-Ghani MA, Matsuda M, Balas B, et al. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care 2007;30:89-94.
15. De Fronzo RA, Abdul-Ghani MA. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 2009;32: e86-e88.
16. Utzschneider KM, Prigeon RL, Faulenbach MV, et al. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 2009;32:335-341.
17. Abdul-Ghani MA, Williams K, DeFronzo R, et al. What is the best predictor of future type 2 diabetes? Diabetes Care 2007;30:1544-1548.
18. National Cholesterol Education Program: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of the High Blood Cholesterol in Adults (ATP III). JAMA 2001;285:2486-2497.
19. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 2005;366:1059-1062.
20. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Available at http://www.idf.org/webdata/docs/IDF- Meta-def.final.pdf.
21. Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.
22. Azevedo A, Bettencourt P, Almeida PB, Santos AC, Abreu-Lima C, Hense H-S, Baroos H. Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities-cross-sectional study of the general population. BMC Cardiovasc Disord 2007;7:17-26.
23. Cubeddu LX and Hoffmann IS. Metabolic syndrome: An all or none or a continuum load of risk. Metab Syndr Relat Disord 2012;10:14-19.
24. Lee WY, Kwon CH, Rhee EJ, et al. The effect of body mass index and fasting glucose on the relationship between blood pressure and incident diabetes mellitus: A 5-year follow-up study. Hypertens Res 2011;34:1093-1097.